NCT06739317

SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.

•Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib As Conversion Therapy Versus Camrelizumab Combined with Apatinib As First-Line Therapy for Unresectable Hepatocellular Carcinoma: a Prospective, Multicenter, Open-label, Randomized Controlled Clinical Trial.

• Status: Not Yet Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 398 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

•This is a randomized, open-label, multi-center, phases 2 and phase 3 trial to evaluate the efficacy and safety of SBRT combined with Camrelizumab and Apatinib as conversion therapy versus Camrelizumab combined with Apatinib as first-Line therapy for unresectable hepatocellular carcinoma.

Conditions

• Unresectable Hepatocellular Carcinoma (HCC)

Interventions

Type	Name	Description
RADIATION	Radiation	Subjects receive Stereotactic Body Radiotherapy combined with Camrelizumab and Apatinib as conversion therapy.
DRUG	First line therapy	Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.
DRUG	First line therapy	Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.
PROCEDURE	operation	If subjects suitable for hepatic resection after conversion therapy, radical surgery and postoperative adjuvant therapy will be performed.

Timeline

• Start date: 2025-01-01
• Primary completion: 2030-12-31
• Completion: 2031-06-30
• First posted: 2024-12-18
• Last updated: 2024-12-18

Locations

1 site across 1 country: China